Curis
Cambridge
About Curis
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $274.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Jan 2026)
- Ticker: nasdaq:CRIS
- Website: curis.comindex.php
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/curis-39794 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.